Lymphocyte activation induces cell surface expression of an immunogenic vimentin isoform

Transplant Immunology

Volumn 27, Issue 2-3, 2012, Pages 101-106

  Bilalic, Senada ^a   Michlmayr, Anna ^a   Gruber, Viktoria ^a   Buchberger, Elisabeth ^a   Burghuber, Christopher ^a   Böhmig, Georg A ^a   Oehler, Rudolf ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cell surface expression; Lymphocyte activation; Renal transplantation; Vimentin

Indexed keywords

CONCANAVALIN A; ISOPROTEIN; VIMENTIN;

ADULT; ANTIGEN BINDING; ARTICLE; CELL SURFACE; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEMODIALYSIS PATIENT; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; LYMPHOCYTE ACTIVATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VOLUNTEER; WESTERN BLOTTING;

ADULT; CELL MEMBRANE; CELLS, CULTURED; CHRONIC DISEASE; FEMALE; GRAFT REJECTION; HUMANS; ISOANTIBODIES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROTEIN BINDING; PROTEIN ISOFORMS; RENAL DIALYSIS; VIMENTIN; WAITING LISTS;

EID: 84868382000     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2012.06.006     Document Type: Article

References (29)

1. Jurcevic S., Ainsworth M.E., Pomerance A., Smith J.D., Robinson D.R., Dunn M.J., et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001, 71:886-892.
2. Mahesh B., Leong H.S., McCormack A., Sarathchandra P., Holder A., Rose M.L. Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. Am J Pathol 2007, 170:1415-1427.
3. Mahesh B., Leong H.S., Nair K.S., McCormack A., Sarathchandra P., Rose M.L. Autoimmunity to vimentin potentiates graft vasculopathy in murine cardiac allografts. Transplantation 2010, 90:4-13.
4. Barber L.D., Whitelegg A., Madrigal J.A., Banner N.R., Rose M.L. Detection of vimentin-specific autoreactive CD8+ T cells in cardiac transplant patients. Transplantation 2004, 77:1604-1609.
5. Jonker M., Danskine A., Haanstra K., Wubben J., Kondova I., Kuhn E.M., et al. The autoimmune response to vimentin after renal transplantation in nonhuman primates is immunosuppression dependent. Transplantation 2005, 80:385-393.
6. Yang L., Lu Y.P., Luo G.H., Song J., Tu Z.D., Li Y.P. C4d deposition is correlated with the level of antivimentin antibody in rat kidneys undergoing chronic allograft nephropathy. Transplant Proc 2008, 40:2786-2789.
7. Bilalic S., Veitinger M., Ahrer K.H., Gruber V., Zellner M., Brostjan C., et al. Identification of Non-HLA antigens targeted by alloreactive antibodies in patients undergoing chronic hemodialysis. J Proteome Res 2010, 9:1041-1049.
8. Huet D., Bagot M., Loyaux D., Capdevielle J., Conraux L., Ferrara P., et al. SC5 mAb represents a unique tool for the detection of extracellular vimentin as a specific marker of Sezary cells. J Immunol 2006, 176:652-659.
9. Moisan E., Girard D. Cell surface expression of intermediate filament proteins vimentin and lamin B1 in human neutrophil spontaneous apoptosis. J Leukoc Biol 2006, 79:489-498.
10. Mor-Vaknin N., Punturieri A., Sitwala K., Markovitz D.M. Vimentin is secreted by activated macrophages. Nat Cell Biol 2003, 5:59-63.
11. Zellner M., Babeluk R., Diestinger M., Pirchegger P., Skeledzic S., Oehler R. Fluorescence-based Western blotting for quantitation of protein biomarkers in clinical samples. Electrophoresis 2008, 29:3621-3627.
12. Prasad S.C., Thraves P.J., Kuettel M.R., Srinivasarao G.Y., Dritschilo A., Soldatenkov V.A. Apoptosis-associated proteolysis of vimentin in human prostate epithelial tumor cells. Biochem Biophys Res Commun 1998, 249:332-338.
13. Podor T.J., Singh D., Chindemi P., Foulon D.M., McKelvie R., Weitz J.I., et al. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. J Biol Chem 2002, 277:7529-7539.
14. Boilard E., Bourgoin S.G., Bernatchez C., Surette M.E. Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2. Blood 2003, 102:2901-2909.
15. Xu B., deWaal R.M., Mor-Vaknin N., Hibbard C., Markovitz D.M., Kahn M.L. The endothelial cell-specific antibody PAL-E identifies a secreted form of vimentin in the blood vasculature. Mol Cell Biol 2004, 24:9198-9206.
16. Ohsaki H., Hirakawa E., Nakamura M., Norimatsu Y., Kiyomoto H., Haba R. Expression of vimentin and high-molecular-weight cytokeratin (clone 34ssE12) in differentiating reactive renal tubular cells from low-grade urothelial carcinoma cells in voided urine. Cytopathology 2011, 22:247-252.
17. Muramatsu M., Miyagi M., Ishikawa Y., Aikawa A., Mizuiri S., Ohara T., et al. Estimation of damaged tubular epithelium in renal allografts by determination of vimentin expression. Int J Urol 2004, 11:954-962.
18. Vansthertem D., Gossiaux A., Decleves A.E., Caron N., Nonclercq D., Legrand A., et al. Expression of nestin, vimentin, and NCAM by renal interstitial cells after ischemic tubular injury. J Biomed Biotechnol 2010, 2010:193259.
19. de Matos A.C., Camara N.O., Tonato E.J., de Souza Durão Júnior M., Franco M.F., Moura L.A., et al. Vimentin expression and myofibroblast infiltration are early markers of renal dysfunction in kidney transplantation: an early stage of chronic allograft dysfunction?. Transplant Proc 2010, 42:3482-3488.
20. Hong S.H., Misek D.E., Wang H., Puravs E., Hinderer R., Giordano T.J., et al. Identification of a specific vimentin isoform that induces an antibody response in pancreatic cance r. Biomark Insights 2006, 1:175-183.
21. Vossenaar E.R., Despres N., Lapointe E., van der Heijden A., Lora M., Senshu T., et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004, 6:R142-R150.
22. De Souza A.I., McGregor E., Dunn M.J., Rose M.L. Preparation of human heart for laser microdissection and proteomics. Proteomics 2004, 4:578-586.
23. Ferry B.L., Welsh K.I., Dunn M.J., Law D., Proctor J., Chapel H., et al. Anti-cell surface endothelial antibodies in sera from cardiac and kidney transplant recipients: association with chronic rejection. Transpl Immunol 1997, 5:17-24.
24. Jurcevic S., Dunn M.J., Crisp S., Busing K., Rinaldi M., Pellegrini C., et al. A new enzyme-linked immunosorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine. Transplantation 1998, 65:1197-1202.
25. McManus C.A., Rose M.L., Dunn M.J. Proteomics of transplant rejection. Transplant Rev 2006, 20:195-207.
26. Wheeler C.H., Collins A., Dunn M.J., Crisp S.J., Yacoub M.H., Rose M.L. Characterization of endothelial antigens associated with transplant-associated coronary artery disease. J Heart Lung Transplant 1995, 14.
27. Azimzadeh A.M., Pfeiffer S., Wu G.S., Schroder C., Zhou H., Zorn G.L., et al. Humoral immunity to vimentin is associated with cardiac allograft injury in nonhuman primates. Am J Transplant 2005, 5:2349-2359.
28. Leong H.S., Mahesh B.M., Day J.R., Smith J.D., McCormack A.D., Ghimire G., et al. Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates via platelet-activating factor. J Leukoc Biol 2008, 83:263-271.
29. Byun Y., Chen F., Chang R., et al. Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. Cell Death Differ 2001, 8:443-450.